PD-1 single domain antibodies and therapeutic compositions thereof
US12297271B2 · kind B2 · utility
0Cited by
33References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2024 |
| Grant date | May 13, 2025 |
| Priority date | — |
| Expiry date | Feb 28, 2044 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.